secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001477932-24-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer
--------------------------------------------------------------------------------

- Received $13.0 million in milestone payments from Heska Corporation.
- Milestone triggered by successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ point-of-care platform.
- Payment stems from March 2022 License and Supply Agreement between Belgian Volition SRL and Heska.
- Test is marketed as the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/0001477932-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer